Synaffix BV Revenue and Competitors
Estimated Revenue & Valuation
- Synaffix BV's estimated annual revenue is currently $6.4M per year.
- Synaffix BV's estimated revenue per employee is $155,000
Employee Data
- Synaffix BV has 41 Employees.
- Synaffix BV grew their employee count by 0% last year.
Synaffix BV's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Business Development | Reveal Email/Phone |
2 | VP CMC and Regulatory | Reveal Email/Phone |
3 | CMC Project Manager | Reveal Email/Phone |
4 | Projectmanager R&D external collaborations | Reveal Email/Phone |
5 | Senior Scientist | Reveal Email/Phone |
6 | Research Associate | Reveal Email/Phone |
7 | Research associate | Reveal Email/Phone |
8 | Research Associate Bioconjugation | Reveal Email/Phone |
9 | Research associate | Reveal Email/Phone |
10 | Research Associate (Organic Chemistry) | Reveal Email/Phone |
Synaffix BV Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Synaffix BV?
Synaffix BV is a Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability of ADC drugs compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) that enables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035. Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products using our proprietary technology. We anticipate first-in-human studies with ADCs prepared using Synaffix technology to be initiated by our partners in 2018. We are backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and M Ventures.
keywords:N/A
N/A
Total Funding
41
Number of Employees
$6.4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.1M | 41 | 0% | N/A |
#2 | $8.1M | 41 | 5% | N/A |
#3 | $7.7M | 41 | 41% | N/A |
#4 | $5.7M | 41 | -27% | N/A |
#5 | $7.5M | 41 | 17% | N/A |